Search hospitals > California > San Diego
VA San Diego Healthcare System, San Diego, CA
Claim this profileSan Diego, California 92103
Global Leader in Post-Traumatic Stress Disorder
Global Leader in Traumatic Stress Disorders
Conducts research for Depression
Conducts research for Schizophrenia
Conducts research for Traumatic Brain Injury
225 reported clinical trials
33 medical researchers
Summary
VA San Diego Healthcare System, San Diego, CA is a medical facility located in San Diego, California. This center is recognized for care of Post-Traumatic Stress Disorder, Traumatic Stress Disorders, Depression, Schizophrenia, Traumatic Brain Injury and other specialties. VA San Diego Healthcare System, San Diego, CA is involved with conducting 225 clinical trials across 293 conditions. There are 33 research doctors associated with this hospital, such as Leslie A. Morland, PsyD, Catherine R Ayers, PhD, Peter Colvonen, MD, and Ariel J. Lang, PhD.Top PIs
Leslie A. Morland, PsyDVA San Diego Healthcare System, San Diego, CA2 years of reported clinical research
Studies Post-Traumatic Stress Disorder
Studies Traumatic Stress Disorders
4 reported clinical trials
6 drugs studied
Catherine R Ayers, PhDVA San Diego Healthcare System, San Diego, CA8 years of reported clinical research
Studies Obsessive Hoarding
Studies Hoarding Disorder
3 reported clinical trials
6 drugs studied
Peter Colvonen, MDVA San Diego Healthcare System, San Diego, CA1 year of reported clinical research
Studies Post-Traumatic Stress Disorder
Studies Traumatic Stress Disorders
3 reported clinical trials
5 drugs studied
Ariel J. Lang, PhDVA San Diego Healthcare System, San Diego, CA1 year of reported clinical research
Studies Post-Traumatic Stress Disorder
Studies Depression
3 reported clinical trials
6 drugs studied
Clinical Trials running at VA San Diego Healthcare System, San Diego, CA
Post-Traumatic Stress Disorder
Depression
Mental Illness
Obstructive Sleep Apnea
Sleep Apnea
Psychosis
Suicide
Chronic Pain
Traumatic Brain Injury
Parkinson's Disease
Prolonged Exposure Therapy + Medication
for PTSD
Posttraumatic Stress Disorder (PTSD) remains a salient and debilitating problem, in the general population and for military veterans in particular. Several psychological and pharmacological treatments for PTSD have evidence to support their efficacy. However, the lack of comparative effectiveness data for PTSD treatments remains a major gap in the literature, which limits conclusions that can be drawn about which of these treatments work best. The current study will compare the effectiveness of PTSD treatments with the strongest evidentiary support - Prolonged Exposure (PE) therapy and pharmacotherapy with paroxetine or venlafaxine - as well as the combination of these two treatments. A randomized trial will be conducted with a large, diverse sample of veterans with PTSD (N = 450) recruited from 6 VA Medical Centers throughout the US. Participants will complete baseline assessments, followed by an active treatment phase (involving up to 14 sessions of PE and/or medication management) with mid (7 week) and posttreatment (14 week) assessments, and follow-up assessments at 27 and 40 weeks. Study outcomes will include PTSD severity, depression, quality of life and functioning, assessed via clinical ratings and self-report measures. Further, a range of demographic and clinically relevant variables (e.g., trauma type/number, resilience) will be collected at baseline and examined as potential predictors or moderators of treatment response, addressing another gap in the PTSD treatment literature. These data will be used to develop algorithms from predicting the optimal treatment for individual patients (i.e., "personalized advantage indices"; PAIs). Effectiveness of the treatments will be compared using multilevel modeling. PAIs will be developed by conducting bootstrapped analyses to select variables that predict or moderate outcomes (clinician rated PTSD severity at Week 14), followed by jacknife analyses to determine the magnitude of the predicted difference (representing an individual's "predicted advantage" of one treatment over the others).
Recruiting3 awards Phase 44 criteria
MDMA-Assisted Therapy
for PTSD
The goal of this pilot trial is to examine the preliminary effectiveness of MDMA-facilitated bCBCT for improving chronic PTSD and relationship functioning in a sample of veterans and their intimate partners seeking care within the VA San Diego Healthcare System.
Recruiting2 awards Phase 3
CBD + Prolonged Exposure
for PTSD
The trial will include a randomized control trial to evaluate the efficacy of using Cannabidiol (CBD), a non-intoxicating cannabinoid, as an adjunctive to Prolonged Exposure therapy (PE). The trial will compare PE + CBD to PE + placebo in a sample of 136 military Veterans with PTSD at the VA San Diego Medical Center. The study represents the logical and innovative next step for augmenting existing treatments and developing novel pharmacotherapy for PTSD. Findings from the proposed RCT will inform clinical practice and policy by investigating whether administration of CBD in the context of PE therapy will improve treatment outcomes for military Veterans with PTSD.
Recruiting2 awards Phase 2
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at VA San Diego Healthcare System, San Diego, CA?
VA San Diego Healthcare System, San Diego, CA is a medical facility located in San Diego, California. This center is recognized for care of Post-Traumatic Stress Disorder, Traumatic Stress Disorders, Depression, Schizophrenia, Traumatic Brain Injury and other specialties. VA San Diego Healthcare System, San Diego, CA is involved with conducting 225 clinical trials across 293 conditions. There are 33 research doctors associated with this hospital, such as Leslie A. Morland, PsyD, Catherine R Ayers, PhD, Peter Colvonen, MD, and Ariel J. Lang, PhD.